Intuitive names Dave Rosa as new CEO starting July 1

SUNNYVALE, Calif. - Intuitive Surgical, Inc. (NASDAQ: ISRG), a robotic surgery giant with a market capitalization of $202.84 billion and "GREAT" financial health according to InvestingPro, announced a significant leadership transition today. Dave Rosa, the company’s current President, has been promoted to Chief Executive Officer, effective July 1, 2025. Gary Guthart, who has been at the helm for 15 years, will transition to the role of Executive Chair of the Board of Directors. Concurrently, Craig Barratt, the current Board Chair, will take on the position of Lead Independent Director.

This reshuffle comes as part of a planned succession strategy, with Rosa being recognized for his vital contributions to Intuitive’s strategic direction, product development, and international expansion. The transition comes at a time when the company is showing strong momentum, with revenue growth of 19.08% and a remarkable 41.7% stock price return over the past year. Barratt expressed confidence in Rosa’s ability to steer the company’s growth into the future.

Guthart praised Rosa’s patient-first approach and his extensive experience with Intuitive’s operations and strategy. He also reflected on his tenure, highlighting the positive impact the company’s products have had on patient care. Rosa, an Intuitive veteran of 29 years, expressed his commitment to advancing the Quintuple Aim—improving patient outcomes, enhancing patient and care team experience, expanding access to care, and reducing healthcare costs.

Rosa’s career at Intuitive began in 1996, and he has since played a crucial role in the development and launch of several of the company’s key products, including the da Vinci SP system and the Ion robotic bronchoscopy system. His ascent to President occurred in 2023, and he joined the board of directors in 2024.

Intuitive is celebrating its 30th anniversary this year, marking three decades of innovation in minimally invasive care. The company reports nearly 17 million da Vinci procedures performed and training provided to almost 90,000 surgeons worldwide. While trading at a premium with a P/E ratio of 81.08, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. Discover detailed valuation metrics and 15 additional ProTips with an InvestingPro subscription, including the comprehensive Pro Research Report available for this leading healthcare innovator.

The information in this article is based on a press release statement from Intuitive Surgical, Inc.

In other recent news, Intuitive Surgical has announced a substantial increase in its stock repurchase program, planning to buy back up to $4 billion of its own shares. This development has contributed to a favorable outlook from Wolfpack Research, which has taken a long position on the company. Additionally, Intuitive Surgical received FDA clearance for its da Vinci Single Port surgical system for use in colorectal surgery, enhancing its utility and expanding its surgical capabilities. In terms of earnings, Stifel analysts have maintained a Buy rating for Intuitive Surgical, citing strong first-quarter procedure growth and an increase in the company’s procedure growth guidance for 2025. However, the company anticipates a negative impact on its gross margin due to tariffs, which has been factored into revised forecasts by Stifel. Meanwhile, RBC Capital Markets has adjusted its price target for Intuitive Surgical to $605, maintaining an Outperform rating despite tariff-related risks. These recent developments reflect Intuitive Surgical’s commitment to shareholder value and its continued growth in the surgical technology market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.